ACADIA Pharmaceuticals Inc.ACADNASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank26
3Y CAGR-24.2%
5Y CAGR+40.1%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-24.2%/yr
vs -29.4%/yr prior
5Y CAGR
+40.1%/yr
Recent deceleration
Acceleration
+5.1pp
Accelerating
Percentile
P26
Within normal range
vs 5Y Ago
5.4x
Strong expansion
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.92% |
| Q3 2025 | 5.32% |
| Q2 2025 | 8.29% |
| Q1 2025 | -5.89% |
| Q4 2024 | 3.67% |
| Q3 2024 | 3.49% |
| Q2 2024 | 17.55% |
| Q1 2024 | -10.91% |
| Q4 2023 | 9.14% |
| Q3 2023 | 28.12% |
| Q2 2023 | 39.48% |
| Q1 2023 | -13.21% |
| Q4 2022 | 4.42% |
| Q3 2022 | -2.86% |
| Q2 2022 | 16.54% |
| Q1 2022 | -11.69% |
| Q4 2021 | -0.65% |
| Q3 2021 | 14.23% |
| Q2 2021 | 8.13% |
| Q1 2021 | -11.94% |
| Q4 2020 | 0.36% |
| Q3 2020 | 9.51% |
| Q2 2020 | 22.24% |
| Q1 2020 | -8.40% |
| Q4 2019 | 3.95% |
| Q3 2019 | 13.68% |
| Q2 2019 | 32.16% |
| Q1 2019 | 5.69% |
| Q4 2018 | 2.17% |
| Q3 2018 | 2.18% |
| Q2 2018 | 16.77% |
| Q1 2018 | 12.18% |
| Q4 2017 | 22.44% |
| Q3 2017 | 16.74% |
| Q2 2017 | 99.37% |
| Q1 2017 | 27.79% |
| Q4 2016 | 127.07% |
| Q3 2016 | 5330.93% |
| Q2 2016 | 2325.00% |
| Q1 2016 | -76.47% |